A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries

Haemophilia

Volumn 19, Issue 1, 2013, Pages 44-50

  Noone, D ^a   O'Mahony, B ^a   van Dijk, J P ^b,c   Prihodova, L ^b  

^a IRISH HAEMOPHILIA SOCIETY   (Ireland)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c P J AFÁRIK UNIVERSITY   (Slovakia)

Author keywords

EQ 5D; Haemophilia; On demand; Prophylaxis

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BLEEDING; CANADA; DISEASE SEVERITY; FRANCE; HEALTH CARE UTILIZATION; HEALTH SURVEY; HEMOPHILIA; HUMAN; IRELAND; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PAIN; POLAND; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SELF EVALUATION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; UNITED KINGDOM;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; CANADA; COAGULANTS; FACTOR IX; FACTOR VIII; FRANCE; GREAT BRITAIN; HEALTH STATUS; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; IRELAND; MALE; NETHERLANDS; POLAND; QUESTIONNAIRES; YOUNG ADULT;

EID: 84870988601     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2012.02934.x     Document Type: Article

References (16)

1. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders - a United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline-approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
2. Ludlam C, Mannucci P, Powderly W. European Interdisciplinary Working. Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group. Haemophilia 2005; 11: 433-7.
3. Manco-Johnson M. Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice. Haemophilia 2007; 13: 4-9.
4. van Dijk K, Fischer K, van der Bom J, Scheibel E, Ingerslev J, van den Berg H. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol 2005; 130: 107-12.
5. Collins P, Faradji A, Morfini M et al. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. Blood 2008; 112: 194-5.
6. Tagliaferri A, Franchini M, Coppola A et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia 2008; 14: 945-51.
7. Noone D, O'Mahony B, Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries. Haemophilia 2011; 17: E842-3.
8. Fischer K, Van der Bom J, Van den Berg H. Health-related quality of life as outcome parameter in haemophilia treatment. Haemophilia 2003; 9: 75-81.
9. Busschbach J, McDonnell J, Essink-Bot M, van Hout B. Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D. J Health Econ 1999; 18: 551-71.
10. Carcao M, Chambost H, Ljung R. Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies. Haemophilia 2010; 16: 4-9.
11. Lippert B, Berger K, Berntorp E et al. European Haemophilia Economic Study. Cost effectiveness of haemophilia treatment: a cross-national assessment. Blood Coagulation Fibrinol 2005; 16: 477-85.
12. Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A RID A-8586-2011. Haemophilia 2008; 14: 743-52.
13. Royal S, Schramm W, Berntorp E et al. European Haemophilia Economic Study. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002; 8: 44-50.
14. Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value in Health 2011; 14: 539-45.
15. Taylor W, Lord S, McPherson K, McNaughton H. EuroQol EQ-5D may not adequately describe the health of people with disabilities. Disabil Rehabil 2001; 23: 281-5.
16. O'Mahony B, Noone D, Tolley K. An introduction to key concepts. Health Economics For Haemophilia Organisations 2010; WFH Monograph: 21-8.